West Pharmaceutical Services, Inc. $WST Shares Acquired by USS Investment Management Ltd

USS Investment Management Ltd lifted its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 16.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,443 shares of the medical instruments supplier’s stock after purchasing an additional 20,100 shares during the quarter. USS Investment Management Ltd’s holdings in West Pharmaceutical Services were worth $53,159,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Private Advisor Group LLC grew its position in West Pharmaceutical Services by 158.5% in the 3rd quarter. Private Advisor Group LLC now owns 2,143 shares of the medical instruments supplier’s stock valued at $795,000 after buying an additional 1,314 shares during the last quarter. Ieq Capital LLC purchased a new position in West Pharmaceutical Services during the 3rd quarter worth $551,000. Meeder Asset Management Inc. raised its position in West Pharmaceutical Services by 39.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 15,260 shares of the medical instruments supplier’s stock worth $5,658,000 after buying an additional 4,349 shares during the last quarter. Composition Wealth LLC purchased a new position in West Pharmaceutical Services during the 3rd quarter worth $229,000. Finally, Voya Investment Management LLC lifted its stake in shares of West Pharmaceutical Services by 0.6% in the 3rd quarter. Voya Investment Management LLC now owns 14,316 shares of the medical instruments supplier’s stock worth $5,308,000 after acquiring an additional 92 shares during the period. 93.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other West Pharmaceutical Services news, VP Annette Favorite sold 2,524 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $365.00, for a total transaction of $921,260.00. Following the transaction, the vice president directly owned 21,818 shares in the company, valued at approximately $7,963,570. This represents a 10.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 15,659 shares of company stock worth $5,443,749 over the last quarter. 0.60% of the stock is currently owned by insiders.

West Pharmaceutical Services Trading Down 1.7%

NYSE:WST opened at $397.16 on Friday. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $438.27. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.10 and a current ratio of 2.82. The stock has a fifty day moving average price of $385.77 and a two-hundred day moving average price of $324.32. The stock has a market capitalization of $27.67 billion, a price-to-earnings ratio of 44.57, a PEG ratio of 2.46 and a beta of 1.13.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, topping the consensus estimate of $2.20 by $0.46. West Pharmaceutical Services had a net margin of 18.81% and a return on equity of 21.78%. The company had revenue of $874.50 million for the quarter, compared to analyst estimates of $827.12 million. During the same period in the previous year, the firm earned $1.96 EPS. The business’s revenue was up 8.7% on a year-over-year basis. As a group, sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 9.45 earnings per share for the current fiscal year.

West Pharmaceutical Services Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 18th. Investors of record on Wednesday, November 11th were issued a dividend of $0.26 per share. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.22. This represents a $1.04 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Tuesday, November 10th. West Pharmaceutical Services’s payout ratio is presently 11.67%.

Trending Headlines about West Pharmaceutical Services

Investors following WST have been watching these headlines:

  • Positive Sentiment: Zacks Research raised its earnings estimates across several periods. Its FY2026 EPS forecast increased to $9.41 from $8.88, and its FY2028 forecast rose to $11.46 from $10.74. The higher projections suggest improved expectations for future earnings; the FY2026 estimate is also close to the $9.45 consensus cited in the reports. West Pharmaceutical Services coverage
  • Positive Sentiment: A recent Zacks article cited strong demand for high-value products, expanding biologics exposure and regulatory upgrades as growth supports, while acknowledging near-term headwinds. Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
  • Neutral Sentiment: Despite raising its estimates, Zacks Research maintained a “Hold” rating. The revisions are encouraging but represent one research firm’s forecasts, not a broad upgrade in analyst recommendations. West Pharmaceutical Services analyst coverage

Analysts Set New Price Targets

WST has been the topic of several analyst reports. Citigroup lifted their target price on shares of West Pharmaceutical Services from $412.00 to $494.00 and gave the company a “buy” rating in a report on Friday, October 30th. Morgan Stanley raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $365.00 to $400.00 in a report on Tuesday, September 22nd. UBS Group raised their price objective on shares of West Pharmaceutical Services from $340.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Evercore reaffirmed an “outperform” rating and issued a $425.00 price objective on shares of West Pharmaceutical Services in a report on Monday, July 27th. Finally, Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, November 2nd. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus target price of $424.67.

Get Our Latest Analysis on West Pharmaceutical Services

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.

See Also

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.